Microba Co-founders and Senior Bioinformatician named as Highly Cited Researchers
Media Announcement Wednesday 20 November 2019
Gut microbiome analysis experts Microba had three of their researchers – including both co-founders – named in the 2019 Highly Cited Researchers list by the Web of Science Group released yesterday.
Professors Gene Tyson and Phil Hugenholtz – Microba co-founders and world-leading experts in microbiome analysis – and Dr Donovan Parks – Senior Bioinformatician with Microba – were all recognised for 2019.
The highly anticipated list identifies scientists who produced multiple papers ranking in the top 1% by citations for their field and year of publication, and demonstrate significant research influence among their peers.
The methodology that determines what’s referred to by the organisers as the “who’s who of influential researchers” draws on the data and analysis performed by bibliometric experts from the Institute for Scientific Information at the Web of Science Group.
Professor Hugenholtz has been cited 40,194 times, Professor Tyson has a total of 10,338 citations and Dr Parks has been cited 12,864 times across fields.
Professor Tyson said that it was an honour to be named in the list and have his research referenced by other academics and researchers.
“I congratulate both Phil and Donovan for their inclusion in the list, as well as the others recognised for 2019,” he said.
“Our work at Microba is potentially life-changing, and I’m pleased to see researchers across the globe citing the research of Phil, Donovan and myself as microbiome experts and growing our collective knowledge of this field.”
The 2019 list includes 6,217 highly cited researchers across many fields from nearly 60 nations, with Australia being represented by 271 researchers and academics.
The research of Professors Tyson and Hugenholtz came out of The University of Queensland and formed the foundation of Microba – a world-leading, award-winning gut microbiome analysis company.
Microba was recently awarded the Brisbane Lord Mayor’s Award for Product Innovation and were also represented at the Falling Walls Venture in Berlin as one of a small number of companies chosen to participate from across the globe.
“At Microba, we are continually surprised and humbled by the recognition we have been receiving, and we look forward to advancing our mission of leading microbiome analysis and creating life-changing therapeutics in the future,” Professor Hugenholtz said.